Literature DB >> 20016050

Development of a disease-specific quality of life questionnaire in Addison's disease.

Kristian Løvås1, Suzanne Curran, Marianne Oksnes, Eystein S Husebye, Felicia A Huppert, V Krishna K Chatterjee.   

Abstract

CONTEXT: Patients with Addison's disease reproducibly self-report impairment in specific dimensions of general well-being questionnaires, suggesting particular deficiencies in health-related quality-of-life (HRQoL).
OBJECTIVE: We sought to develop an Addison's disease-specific questionnaire (AddiQoL) that could better quantify altered well-being and treatment effects. Design, Setting, Patients, Intervention, and Outcomes: We reviewed the literature to identify HRQoL issues in Addison's disease and interviewed patients and their partners in-depth to explore various symptom domains. A list of items was generated, and nine expert clinicians and five expert patients assessed the list for impact and clarity. A preliminary questionnaire was presented to 100 Addison's outpatients; the number of items was reduced after analysis of the distribution of the responses. The final questionnaire responses were assessed by Cronbach's alpha and Rasch analysis. RESULTS AND
INTERPRETATION: Published studies of HRQoL in Addison's disease indicated reduced vitality and general health perception and limitations in physical and emotional functioning. In-depth interviews of 14 patients and seven partners emphasized the impact of the disease on the emotional domain. Seventy HRQoL items were generated; after the expert consultation process and pretesting in 100 patients, the number of items was reduced to 36. Eighty-six patients completed the final questionnaire; the responses showed high internal consistency with Cronbach's alpha 0.95 and Person Separation Index 0.94 (Rasch analysis).
CONCLUSIONS: We envisage AddiQoL having utility in trials of hormone replacement and management of patients with Addison's disease, analogous to similar questionnaires in GH deficiency (AGHDA) and acromegaly (AcroQoL).

Entities:  

Mesh:

Year:  2009        PMID: 20016050     DOI: 10.1210/jc.2009-1711

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.

Authors:  Roberta Giordano; Federica Guaraldi; Elisa Marinazzo; Federica Fumarola; Alessia Rampino; Rita Berardelli; Ioannis Karamouzis; Manuela Lucchiari; Tilde Manetta; Giulio Mengozzi; Emanuela Arvat; Ezio Ghigo
Journal:  Endocrine       Date:  2015-07-17       Impact factor: 3.633

2.  Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

Authors:  A M Isidori; G Arnaldi; M Boscaro; A Falorni; C Giordano; R Giordano; R Pivonello; C Pozza; E Sbardella; C Simeoli; C Scaroni; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-11-26       Impact factor: 4.256

Review 3.  Dual-release Hydrocortisone in Addison's Disease - A Review of the Literature.

Authors:  Roberta Giordano; Federica Guaraldi; Rita Berardelli; Ioannis Karamouzis; Valentina D'Angelo; Clizia Zichi; Silvia Grottoli; Ezio Ghigo; Emanuela Arvat
Journal:  Eur Endocrinol       Date:  2014-02-28

4.  Dual-release hydrocortisone and its benefits on cognitive function and quality of sleep.

Authors:  Clarissa Krekeler; Peter Kropp; Antje Katrin Blacha; Amir-Hossein Rahvar; Birgit Harbeck
Journal:  Endocrine       Date:  2021-02-24       Impact factor: 3.633

5.  Episodic memory impairment in Addison's disease: results from a telephonic cognitive assessment.

Authors:  Michelle Henry; Kevin G F Thomas; Ian L Ross
Journal:  Metab Brain Dis       Date:  2014-02-27       Impact factor: 3.584

6.  Poor quality of life, depressed mood, and memory impairment may be mediated by sleep disruption in patients with Addison's disease.

Authors:  Michelle Henry; Pedro S A Wolf; Ian L Ross; Kevin G F Thomas
Journal:  Physiol Behav       Date:  2015-08-07

7.  Longitudinal AddiQoL scores may identify higher risk for adrenal crises in Addison's disease.

Authors:  Gesine Meyer; Maike Koch; Eva Herrmann; Jörg Bojunga; Klaus Badenhoop
Journal:  Endocrine       Date:  2018-01-31       Impact factor: 3.633

Review 8.  Therapy of adrenal insufficiency: an update.

Authors:  Alberto Falorni; Viviana Minarelli; Silvia Morelli
Journal:  Endocrine       Date:  2012-11-21       Impact factor: 3.633

9.  Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey.

Authors:  M Forss; G Batcheller; S Skrtic; G Johannsson
Journal:  BMC Endocr Disord       Date:  2012-06-13       Impact factor: 2.763

Review 10.  Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults.

Authors:  C Betterle; F Presotto; J Furmaniak
Journal:  J Endocrinol Invest       Date:  2019-07-18       Impact factor: 5.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.